← Back to Search

Other

CPI-1189 for AIDS Dementia

Phase 2

Waitlist Available

Research Sponsored by Centaur Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Are at least 18 years old

Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test if it is safe and effective to give CPI-1189 to patients with AIDS dementia.

Who is the study for?

This trial is for HIV-positive adults at least 18 years old who have stable anti-HIV drug therapy and symptoms of AIDS dementia, like forgetfulness or muscle control loss. It's not for those with serious conditions like mental disorders or opportunistic infections.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of CPI-1189 in patients with AIDS dementia, which can cause memory loss and muscle issues due to advanced HIV infection. The goal is to see if CPI-1189 can delay or slow down these symptoms.See study design

What are the potential side effects?

Specific side effects are not listed here, but generally, participants will be monitored for any adverse reactions to CPI-1189 as it relates to their condition of AIDS dementia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I experience symptoms like forgetfulness and loss of muscle control.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Centaur PharmaceuticalsLead Sponsor

1 Previous Clinical Trials

48 Total Patients Enrolled

Clifford DBStudy Chair

Media Library

CPI-1189 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00002414 — Phase 2

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: CPI-1189 Highlights & Side Effects. Trial Name: NCT00002414 — Phase 2

CPI-1189 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002414 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Where are patients able to participate in this clinical trial?

"Right now, there are 6 hospitals enrolling patients for this study. The locations include 3 cities- Baltimore, Rochester and Chicago- as well as 6 additional sites. If you choose to participate in the trial, try and select a location that is close to reduce travel burdens."

Answered by AI

Who would be an appropriate candidate for this type of research?

"Sixty individuals that are infected with HIV and eighteen years or older can participate in this study. Most importantly, potential patients should meet the following guidelines: displaying symptoms related to AIDS dementia such as forgetfulness, muscle control loss, decreased concentration or slow mental processing; a positive HIV diagnosis; being on anti-HIV medication for at least six weeks prior to joining the study (if applicable)."

Answered by AI

Will this experiment be testing its effects on middle-aged adults?

"To meet the requirements for this trial, applicants must be between 18 and 0 years old. Out of the 477 total clinical trials, 110 are for people under 18 while 367 are for seniors."

Answered by AI

Does the FDA sanction this medication?

"While there is some evidence backing the safety of this treatment, it received a 2 because Phase 2 trials have not yet found data supporting efficacy."

Answered by AI

Recent research and studies

NeurologyJournal

A Randomized Clinical Trial of CPI-1189 for Hiv-associated Cognitive-motor Impairment

Clifford, D. B., J. C. McArthur, G. Schifitto, K. Kieburtz, M. P. McDermott, S. Letendre, B. A. Cohen, K. Marder, R. J. Ellis, and C. M. Marra. 2002. “A Randomized Clinical Trial of CPI-1189 for Hiv-associated Cognitive-motor Impairment”. Neurology. Ovid Technologies (Wolters Kluwer Health). doi:10.1212/01.wnl.0000034177.47015.da.

clinicaltrials.govStudy

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

2024. "Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002414.

All > Hiv Infection > Cte